Etazolate

Etazolate
Clinical data
Routes of
administration		 Oral
ATC code none
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 51022-77-6
PubChem (CID) 3277
IUPHAR/BPS 7336
ChemSpider 3162
UNII I89Y79062L YesY
ChEMBL CHEMBL356388
Chemical and physical data
Formula C14H19N5O2
Molar mass 289.33 g/mol
3D model (Jmol) Interactive image

Etazolate (SQ-20,009, EHT-0202) is an anxiolytic drug which is a pyrazolopyridine derivative and has unique pharmacological properties.[1][2][3] It acts as a positive allosteric modulator of the GABAA receptor at the barbiturate binding site,[4][5][6][7] as an adenosine antagonist of the A1 and A2 subtypes,[8] and as a phosphodiesterase inhibitor selective for the PDE4 isoform.[9][10][11] It is currently in clinical trials for the treatment of Alzheimer's disease.[12]

Synthesis

Cartazolate and Etazolate synthesis: E.R. SQUIBB & SONS, INC., NEW YORK, N.Y., US. DE 2123318 

See also

References

  1. ↑ Hall, Judith A.; Morton, Ian (1999). Concise dictionary of pharmacological agents: properties and synonyms. Kluwer Academic. ISBN 0-7514-0499-3.
  2. ↑ Williams M (May 1983). "Anxioselective anxiolytics". Journal of Medicinal Chemistry. 26 (5): 619–28. doi:10.1021/jm00359a001. PMID 6132997.
  3. ↑ Williams M, Risley EA (February 1979). "Enhancement of the binding of 3H-diazepam to rat brain membranes in vitro by SQ 20009, A novel anxiolytic, gamma-aminobutyric acid (GABA) and muscimol". Life Sciences. 24 (9): 833–41. doi:10.1016/0024-3205(79)90367-9. PMID 449623.
  4. ↑ Zezula J, Slany A, Sieghart W (April 1996). "Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits". European Journal of Pharmacology. 301 (1–3): 207–14. doi:10.1016/0014-2999(96)00066-0. PMID 8773466.
  5. ↑ Remington, Gary; Baskys, Andrius (1996). Brain mechanisms and psychotropic drugs. Boca Raton: CRC Press. ISBN 0-8493-8386-2.
  6. ↑ M. Mishina; Kurachi, Yoshihisa (2000). Pharmacology of ionic channel function: activators and inhibitors. Berlin: Springer. ISBN 3-540-66127-1.
  7. ↑ Progress in Drug Research / Volume 31 (Progress in Drug Research). Boston: Birkhauser. 1987. p. 526. ISBN 3-7643-1837-6.
  8. ↑ Williams M, Jarvis MF (February 1988). "Adenosine antagonists as potential therapeutic agents". Pharmacology, Biochemistry, and Behavior. 29 (2): 433–41. doi:10.1016/0091-3057(88)90182-7. PMID 3283781.
  9. ↑ Chasin M, Harris DN, Phillips MB, Hess SM (September 1972). "1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009)--a potent new inhibitor of cyclic 3',5'-nucleotide phosphodiesterases". Biochemical Pharmacology. 21 (18): 2443–50. doi:10.1016/0006-2952(72)90414-5. PMID 4345859.
  10. ↑ Wang P, Myers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM (May 1997). "Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D". Biochemical and Biophysical Research Communications. 234 (2): 320–4. doi:10.1006/bbrc.1997.6636. PMID 9177268.
  11. ↑ Gresele, Paolo; Gresele, P. (2002). Platelets in thrombotic and non-thrombotic disorders: pathophysiology, pharmacology and therapeutics. Cambridge, UK: Cambridge University Press. ISBN 0-521-80261-X.
  12. ↑ "Pipeline | ExonHit". Retrieved August 2010. Check date values in: |access-date= (help)
This article is issued from Wikipedia - version of the 5/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.